Trials / Completed
CompletedNCT00334334
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
To Assess Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Co-administered With DTPa-combined Vaccines and MenC or Hib-MenC Vaccines During the First 6 Months of Age.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,572 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Weeks – 16 Weeks
- Healthy volunteers
- Accepted
Summary
Three dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus influenzae type b.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pneumococcal (vaccine) |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2007-07-01
- Completion
- 2007-08-01
- First posted
- 2006-06-07
- Last updated
- 2016-11-04
Locations
66 sites across 3 countries: Germany, Poland, Spain
Source: ClinicalTrials.gov record NCT00334334. Inclusion in this directory is not an endorsement.